Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 16/20 | 0.40 |
| ▸ | PRMT5 | O14744 | 3/20 | 0.33 |
| ▸ | WDR77 | Q9BQA1 | 3/20 | 0.33 |
| ▸ | AR | P10275 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29565513 | 0.92 | PARP1 (0.43) | PARP1PRMT5WDR77ARCYP3A4 | |
| SCHEMBL29565697 | 0.86 | PARP1 (0.54) | PARP1 | |
| SCHEMBL29565479 | 0.86 | PARP1 (0.45) | PARP1PRMT5WDR77ARHDAC6 | |
| SCHEMBL25890280 | 0.86 | PARP1 (0.43) | PARP1PRMT5WDR77ARHDAC6 | |
| SCHEMBL25315024 | 0.86 | PARP1 (0.43) | PARP1PRMT5WDR77ARHDAC6 | |
| SCHEMBL24389991 | 0.86 | PARP1 (0.45) | PARP1PRMT5WDR77ARHDAC6 | |
| SCHEMBL29565707 | 0.86 | PARP1 (0.43) | PARP1PRMT5WDR77ARCYP3A4 | |
| SCHEMBL29565341 | 0.86 | PARP1 (0.43) | PARP1PRMT5WDR77ARHDAC6 | |
| SCHEMBL25312615 | 0.83 | PARP1 (0.43) | PARP1PRMT5WDR77AR | |
| SCHEMBL30132743 | 0.83 | PARP1 (0.43) | PARP1PRMT5WDR77AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022090938-A1 | PHTHALAZINONE DERIVATIVES USEFUL AS PARP INHIBITORS | RHIZEN PHARMACEUTICALS AG (CH) | 2022-05-05 | — | — | WO | disclosed |